ArticleAnnals of African medicine2026
Differential Mitochondrial DNA Copy Number and Redox/Inflammatory States in Diabetic and Nondiabetic Chronic Kidney Disease: A Study in a South Indian Cohort.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health challenge, with diabetic kidney disease being a major cause in India. Mitochondrial dysfunction is central to kidney injury, and mitochondrial DNA copy number (mtDNA-CN) reflects mitochondrial health. This study compared mtDNA-CN in urine cell pellets from diabetic CKD (DCKD), non-DCKD (NDCKD), and healthy controls (HC) in a South Indian cohort. MATERIALS AND
methodsThis prospective, cross-sectional study included 75 participants (25 DCKD, 25 NDCKD, 25 HC). Urine cell pellet mtDNA-CN was measured by qPCR. Statistical analysis used ANOVA/Kruskal-Wallis tests ( P < 0.05 significant).
resultsParticipants averaged 55.08 ± 13.24 years old. DM patients showed significantly higher mtDNA-CN than non-DM patients (93.96 ± 14.01 vs. 49.04 ± 22.28; P = 0.0001). While no difference existed between CKD Stage III and IV, overall mtDNA-CN varied significantly across No CKD, Stage III, and Stage IV groups ( P = 0.0001). A progressive increase in mtDNA-CN was observed from HC (31.84 ± 13.41) to NDCKD (66.24 ± 14.74) and then to DCKD (93.96 ± 14.01), with highly significant differences among these groups ( P = 0.0001).
conclusionOur findings indicate a progressive increase in urine cell pellet mtDNA-CN across healthy individuals, NDCKD, and DCKD. This pattern, particularly in DCKD, may reflect a compensatory mitochondrial response to metabolic stress, suggesting mtDNA-CN as a promising noninvasive biomarker for disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.